Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

504924 Indomethacin, 2ʹ-Trifluoromethyl - Calbiochem

504924
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₁₉H₁₃ClF₃NO₄
Description
Overview

This product has been discontinued.



A cell-permeable, bioavailable 2′-trifluoromethyl analog of Indomethacin (Cat. No. 405268) that acts as a highly potent, time-dependent inhibitor of cyclooxygenase -2 (COX-2; IC50 = 267 and 388 nM for mouse and human COX-2, respectively) and its several mutant forms. Does not affect COX-1 activity even at high concentrations (IC50 >100 µM). Interacts with human COX-2 with much greater affinity than indomethacin (KI = 1.5 vs 13 µM) and blocks COX-2 dependent arachidonic acid oxygenation (IC50 = 150 nM in 1483 human head and neck squamous cell carcinoma cells). Further, minimizes swelling in carrageenan-induced rat paw edema model (EC50 = 1.7 mg/kg, p.o.) with no gastrointestinal bleeding at higher doses (10 mg/kg).

Catalogue Number504924
Brand Family Calbiochem®
SynonymsIndomethacin, 2ʹ-Trifluoromethyl; Indomethacin, 2-CF₃, CF₃-Indomethacin; CF₃-INDO
References
ReferencesBlobaum, A.L., et al. 2013. ACS Med. Chem. Lett. 4, 486.
Product Information
FormWhite powder
Hill FormulaC₁₉H₁₃ClF₃NO₄
Chemical formulaC₁₉H₁₃ClF₃NO₄
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetCOX-2
Primary Target IC<sub>50</sub>267 and 388 nM for mouse and human COX-2, respectively
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
504924 0

Documentation

Indomethacin, 2ʹ-Trifluoromethyl - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Blobaum, A.L., et al. 2013. ACS Med. Chem. Lett. 4, 486.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision18-October-2013 JSW
SynonymsIndomethacin, 2ʹ-Trifluoromethyl; Indomethacin, 2-CF₃, CF₃-Indomethacin; CF₃-INDO
DescriptionA cell-permeable, bioavailable 2′-trifluoromethyl analog of Indomethacin (Cat. No. 405268) that acts as a highly potent, time-dependent inhibitor of cyclooxygenase -2 (COX-2; IC50 = 267 and 388 nM for mouse and human COX-2, respectively) and its several mutant forms. Does not affect COX-1 activity even at high concentrations (IC50 >100 µM). Interacts with human COX-2 with much greater affinity than indomethacin (KI = 1.5 vs 13 µM) and blocks COX-2 dependent arachidonic acid oxygenation (IC50 = 150 nM in 1483 human head and neck squamous cell carcinoma cells). Further, minimizes swelling in carrageenan-induced rat paw edema model (EC50 = 1.7 mg/kg, p.o.) with no gastrointestinal bleeding at higher doses (10 mg/kg).
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₁₉H₁₃ClF₃NO₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesBlobaum, A.L., et al. 2013. ACS Med. Chem. Lett. 4, 486.